An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.

The authors showed how a coronavirus specific protease inhibitor designed in the lab, that could be administered by mouth to humans, achieved excellent plasma concentrations and antiviral potency. This drug, marketed as Pfizer's Paxlovid, was the first successful outpatient medicine for the treatment of COVID-19.
Order of authorship in the original publication: Owen, Allerton, Anderson.

(Thanks to Juan Weiss for this reference and its interpretation.)